Novel chimeric anti-ricin antibody C4C13 with neutralizing activity against ricin toxicity.
So far, no specific therapeutic agent is available for the treatment of ricin intoxication. Here, V(H) and V(L) genes were cloned from a hybridoma cell line secreting anti-ricin mAb 4C13, which could neutralize the toxicity of ricin. A chimeric antibody, c4C13, containing 4C13 mAb variable region genes fused to human constant region genes (gamma 1, kappa), was constructed. C4C13 retained the binding activity and recognized the same, or a closely related, epitope as the original mouse antibody. Furthermore, c4C13 blocked ricin-induced cytotoxicity to SP2/0 cells. Compared with its parental mouse antibody, c4C13 will be safer when used in human body to reverse clinical ricin intoxication.
Wang
Yugang
Y
Institute of Basic Medical Sciences, Beijing, PR China.
Guo
Leiming
L
Zhao
Kunpeng
K
Chen
Jugao
J
Feng
Jiannan
J
Sun
Yingxun
Y
Li
Yan
Y
Shen
Beifen
B
D000595:Amino Acid Sequence; D000911:Antibodies, Monoclonal / Q000737:chemistry / Q000276:immunology*; D000918:Antibody Specificity / Q000187:drug effects; D001483:Base Sequence; D001666:Binding Sites, Antibody; D001667:Binding, Competitive / Q000187:drug effects; D015153:Blotting, Western; D016923:Cell Death / Q000187:drug effects; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D007135:Immunoglobulin Variable Region / Q000737:chemistry; D019169:Jurkat Cells; D008969:Molecular Sequence Data; D009500:Neutralization Tests; D011994:Recombinant Proteins / Q000737:chemistry / Q000276:immunology*; D012276:Ricin / Q000276:immunology* / Q000633:toxicity*
D000911:Antibodies, Monoclonal; C526001:C4C13 monoclonal antibody; D007135:Immunoglobulin Variable Region; D011994:Recombinant Proteins; D012276:Ricin